Plato Investment Management Ltd Buys Shares of 1,179 United Therapeutics Corporation $UTHR

Plato Investment Management Ltd purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,179 shares of the biotechnology company’s stock, valued at approximately $635,000.

Several other institutional investors have also modified their holdings of the company. Avoro Capital Advisors LLC increased its holdings in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP lifted its position in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC boosted its stake in United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the period. Janus Henderson Group PLC boosted its stake in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the period. Finally, Norges Bank bought a new position in United Therapeutics in the 4th quarter worth about $293,418,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on UTHR. Royal Bank Of Canada cut their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $646.00.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total value of $4,291,515.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $23,356,182.60. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $506.59, for a total transaction of $4,812,605.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $164,359,579.37. This represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 452,575 shares of company stock valued at $245,684,184 over the last three months. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Stock Up 1.9%

Shares of United Therapeutics stock opened at $518.27 on Wednesday. The firm has a market cap of $22.23 billion, a price-to-earnings ratio of 18.54, a price-to-earnings-growth ratio of 1.69 and a beta of 0.59. The business has a fifty day simple moving average of $534.53 and a 200-day simple moving average of $536.74. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $6.41 earnings per share. Analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.